Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report

Clin Lung Cancer. 2020 Jan;21(1):e30-e32. doi: 10.1016/j.cllc.2019.02.004. Epub 2019 Oct 13.
No abstract available

Keywords: Immune-related adverse events; Immunotherapy; NSCLC; PD-1 inhibitors; Severe hepatitis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug-Related Side Effects and Adverse Reactions / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Hepatitis / drug therapy*
  • Hepatitis / etiology
  • Hepatitis / pathology
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology
  • Male
  • Retreatment / methods*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab